Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Haematologica
    September 2025
  1. SANTORO A, Improta CM, Sarina B, Mannina D, et al
    Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma.
    Haematologica. 2025 Sep 18. doi: 10.3324/haematol.2025.287672.
    >> Share

    August 2025
  2. MOLLA R, Bantilan K, Berman E, Caron P, et al
    Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma.
    Haematologica. 2025 Aug 7. doi: 10.3324/haematol.2024.287165.
    >> Share

    July 2025
  3. GHIONE P, Zinzani PL, Brown JR
    Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Haematologica. 2025 Jul 24. doi: 10.3324/haematol.2025.288114.
    >> Share

  4. MOSKOWITZ AJ
    Fit, unfit, or frail? Now easier to tell for Hodgkin lymphoma.
    Haematologica. 2025 Jul 17. doi: 10.3324/haematol.2025.288033.
    >> Share

  5. IACCARINO I, Beder T, Reinke S, Borchmann P, et al
    Long non-coding RNA LINC00926 is a biomarker for naive B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma.
    Haematologica. 2025 Jul 17. doi: 10.3324/haematol.2025.287524.
    >> Share

  6. ALHOMOUD M, Ibrahim R, Demetres M, Rejeski K, et al
    Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.
    Haematologica. 2025 Jul 10. doi: 10.3324/haematol.2025.287547.
    >> Share

  7. SHOUSE G, Chen C, Muir A, Popplewell L, et al
    Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2024.286945.
    >> Share

  8. DANILOV AV, Li H, Shadman M, Rimsza L, et al
    Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial.
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2025.288057.
    >> Share

  9. DOGLIOTTI I, Federico M
    BTKi +humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2025.288196.
    >> Share

    June 2025
  10. ATALLAH-YUNES SA, Rees MJ, Habermann TM, Wang Y, et al
    Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patients.
    Haematologica. 2025 Jun 19. doi: 10.3324/haematol.2025.288145.
    >> Share

  11. SCHMIDT C, Scheubeck G, Jurinovic V, Sokler M, et al
    Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.
    Haematologica. 2025 Jun 12. doi: 10.3324/haematol.2024.287162.
    >> Share

  12. LIA K, Jorgensen RRK, Wikman P, Wold BL, et al
    Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Jun 12. doi: 10.3324/haematol.2025.288284.
    >> Share

  13. XAVIER AC, Liao Y, Cairo MS
    Persistent Epstein-Barr virus viremia in NK-/T-cell lymphoma: bad boys for life!
    Haematologica. 2025 Jun 5. doi: 10.3324/haematol.2025.287922.
    >> Share

  14. HUANG K
    When 'simplified' may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Jun 5. doi: 10.3324/haematol.2025.288186.
    >> Share

  15. AUTIO M, Bruck O, Pollari M, Karjalainen-Lindsberg ML, et al
    Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas.
    Haematologica. 2025;110:1339-1350.
    >> Share

    May 2025
  16. MAGNI M, Jonnalagadda S, Bonifazi F, Bonafe M, et al
    CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.
    Haematologica. 2025 May 29. doi: 10.3324/haematol.2025.287528.
    >> Share

  17. DE GROOT FA, Stedema FG, Kret EJ, De Haan LM, et al
    MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.
    Haematologica. 2025 May 29. doi: 10.3324/haematol.2025.287485.
    >> Share

  18. ARDISSINO G, Angelillo P, Mancuso MC, Griffini S, et al
    Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab.
    Haematologica. 2025 May 15. doi: 10.3324/haematol.2025.287532.
    >> Share

  19. BRISOU G, Paillassa J, Bernard S, Tournilhac O, et al
    Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study.
    Haematologica. 2025 May 15. doi: 10.3324/haematol.2024.287141.
    >> Share

  20. EERTINK JJ, Heymans MW, Wiegers SE, Bes AL, et al
    Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response.
    Haematologica. 2025 May 15. doi: 10.3324/haematol.2024.287241.
    >> Share

    April 2025
  21. SAITO M, Sato T, Hasegawa H, Tanabe K, et al
    Clonality analysis of HTLV-1-infected cells enhances prognostic precision in smoldering adult T-cell leukemia/lymphoma.
    Haematologica. 2025 Apr 30. doi: 10.3324/haematol.2025.287521.
    >> Share

  22. LIA K, Jorgensen RRK, Wikman P, Wold BL, et al
    A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Apr 24. doi: 10.3324/haematol.2025.287509.
    >> Share

  23. LI M, Zhang Y, Zong L, Zhang M, et al
    An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment.
    Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2024.286923.
    >> Share

  24. KIM TM, Lakhani NJ, Soumerai J, Kamdar M, et al
    Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.
    Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2024.286208.
    >> Share

  25. ZHONG H, Cheng S, Xiong J, Chen J, et al
    Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.
    Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2025.287513.
    >> Share

  26. IANNITTO E, Ferrero S, Bommier C, Drandi D, et al
    Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
    Haematologica. 2025;110:1048-1049.
    >> Share

  27. JACQUEMIN G, Granci V, Gallouet AS, Lalaoui N, et al
    Erratum to: Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.
    Haematologica. 2025;110:1047.
    >> Share

    March 2025
  28. IGLESIAS R, Diaz E, Fernandez S, Miguelez M, et al
    Clonal hematopoiesis is common in bone marrow of patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Mar 20. doi: 10.3324/haematol.2024.286579.
    >> Share

  29. PORTUGUESE AJ, Huang JJ, Jeon Y, Taheri M, et al
    Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up.
    Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287010.
    >> Share

  30. YAN M, Sethi S, Kumar J, Kumar A, et al
    Leukemic presentation in nodal mantle cell lymphoma is characterized by frequent SOX11 negativity, a poor risk genomic landscape including higher TP53 alterations, and worse overall survival.
    Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287108.
    >> Share

  31. BOARDMAN AP, Gutgarts V, Flynn J, Devlin SM, et al
    Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.
    Haematologica. 2025;110:651-664.
    >> Share

  32. GHOSH N, Sehgal A, Liu FF, Kostic A, et al
    Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world.
    Haematologica. 2025;110:693-705.
    >> Share

    February 2025
  33. ALVEY EN, Yap KL, Rathbun P, Fitzpatrick C, et al
    B-cell lymphoblastic leukemia/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.
    Haematologica. 2025 Feb 27. doi: 10.3324/haematol.2024.286626.
    >> Share

  34. EL DAKER S, Qualls D, Derkach A, Beqaj S, et al
    Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment.
    Haematologica. 2025 Feb 6. doi: 10.3324/haematol.2024.286383.
    >> Share

  35. MINSON AG, Dickinson MJ
    New bispecific antibodies in diffuse large B-cell lymphoma.
    Haematologica. 2025 Feb 6. doi: 10.3324/haematol.2024.285343.
    >> Share

  36. WILLSCHER E, Schultheiss C, Paschold L, Lea Schumann F, et al
    T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.
    Haematologica. 2025;110:457-469.
    >> Share

    January 2025
  37. DOUGLAS G, Nicholls KM, Paul E, Loh Z, et al
    Opportunistic bone density assessment using pre-treatment [18F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy.
    Haematologica. 2025 Jan 23. doi: 10.3324/haematol.2024.286618.
    >> Share

  38. WENDLER J, Lewis RI, Kutilina A, Knott M, et al
    Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.
    Haematologica. 2025 Jan 23. doi: 10.3324/haematol.2024.286347.
    >> Share

  39. HUGHES AD, Polonen P, Teachey DT
    Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
    Haematologica. 2025 Jan 9. doi: 10.3324/haematol.2024.285643.
    >> Share

  40. SHAH NN, Wang M, Roeker LE, Patel K, et al
    Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
    Haematologica. 2025;110:92-102.
    >> Share

  41. STEPHAN P, Perrot J, Voisin A, Barbery M, et al
    Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.
    Haematologica. 2025;110:129-141.
    >> Share

    December 2024
  42. SOSCIA R, Assanto GM, Starza ID, Moia R, et al
    Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma.
    Haematologica. 2024 Dec 19. doi: 10.3324/haematol.2024.286331.
    >> Share

  43. DE MATTEIS S, Del Coco L, De Castro F, Giudetti AM, et al
    Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome.
    Haematologica. 2024 Dec 19. doi: 10.3324/haematol.2024.285154.
    >> Share

  44. BIEDERMANN A, Patra-Kneuer M, Mougiakakos D, Buttner-Herold M, et al
    Blockade of the CD47/SIRPalpha checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.
    Haematologica. 2024;109:3928-3940.
    >> Share

    November 2024
  45. NI V, Nasta SD, Barta SK, Schuster SJ, et al
    Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP.
    Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286560.
    >> Share

  46. FALCHI L, Hutchings M, Carlo-Stella C, Morschhauser F, et al
    Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma.
    Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286257.
    >> Share

  47. ZELIKSON V, Gurumurthi A, Sawalha Y, Annunzio K, et al
    Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.
    Haematologica. 2024 Nov 14:0. doi: 10.3324/haematol.2024.285977.
    >> Share

  48. LEMONNIER F, Philippe G
    In T-follicular helper lymphomas, 'one lymphoma can hide another': beginning to explain.
    Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.286173.
    >> Share

  49. GRAINGER BT, Cheah CY
    "The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors.
    Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.286205.
    >> Share

  50. BARON M, Labreche K, Veyri M, Desire N, et al
    Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments.
    Haematologica. 2024;109:3615-3630.
    >> Share

    October 2024
  51. VALCARCEL B, Schonfeld SJ, Shiels MS, Castillo JJ, et al
    Survival outcomes in diffuse large B-cell lymphoma patients with and without HIV in the United States from 2001 to 2016: a population-based analysis.
    Haematologica. 2024 Oct 31. doi: 10.3324/haematol.2024.286343.
    >> Share

  52. NIZAMUDDIN IA, Bartlett NL
    Bispecific antibodies in follicular lymphoma.
    Haematologica. 2024 Oct 31. doi: 10.3324/haematol.2024.285245.
    >> Share

  53. BRIEGHEL C, Petersen SL, Brown PN, Niemann CU, et al
    Frequency of secondary T-cell lymphoma in chimeric antigen receptor Tcell naive B-cell lymphoid-lineage cancers is higher than that reported on chimeric antigen receptor T-cell therapy.
    Haematologica. 2024 Oct 17. doi: 10.3324/haematol.2024.286002.
    >> Share

  54. ATALLAH-YUNES SA, Rees MJ, Witzig TE, Habermann TM, et al
    CODOX-M/IVAC-R versus DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under.
    Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.286168.
    >> Share

  55. DOGAN A, Roshal M
    Challenges in defining the immune microenvironment in T-cell lymphoma.
    Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.285836.
    >> Share

  56. BAGGIO D, Cwynarski K
    Thiotepa-based autograft for primary central nervous system lymphoma.
    Haematologica. 2024;109:3083-3084.
    >> Share

  57. VALCARCEL B, Schonfeld SJ, Jackson SS, Dores GM, et al
    Changes in sex-specific incidence of lymphoid neoplasms across the lifespan.
    Haematologica. 2024;109:3408-3413.
    >> Share

  58. TARANTELLI C, Wald D, Munz N, Spriano F, et al
    Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.
    Haematologica. 2024;109:3314-3326.
    >> Share

    September 2024
  59. GUAN X, Wang Y, Fang T, Wang J, et al
    Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large Bcell lymphomas and regulates the pro-tumor microenvironment.
    Haematologica. 2024 Sep 26. doi: 10.3324/haematol.2024.285304.
    >> Share

  60. CROCHET G, Houot R
    Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma": chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies.
    Haematologica. 2024 Sep 19. doi: 10.3324/haematol.2024.286353.
    >> Share

  61. MERCADAL S, Ahn KW, Allbee-Johnson M, Ganguly S, et al
    Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285613.
    >> Share

  62. LIN N, Sun X, Zhou H, Zou L, et al
    Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.284973.
    >> Share

  63. CASSANELLO G, Drill E, Rivas-Delgado A, Okwali M, et al
    Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285600.
    >> Share

  64. PHILLIPS T, Wang M, Robak T, Gallinson D, et al
    Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2023.284896.
    >> Share

  65. SALVARIS RT, Allanson BM, Collins G, Cheah C, et al
    Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285903.
    >> Share

  66. URAK R, Pahlavanneshan S, Gittins B, Nakamura R, et al
    Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells.
    Haematologica. 2024;109:3053-3058.
    >> Share

  67. ALENCAR AJ, Alderuccio JP
    Not all central nervous system lymphomas are created equal.
    Haematologica. 2024;109:2769-2771.
    >> Share

    August 2024
  68. PILERI SA
    Entities versus diseases: Myers et al. propose distinct aspects of adult T-cell lymphoma/leukemia.
    Haematologica. 2024 Aug 29. doi: 10.3324/haematol.2024.286174.
    >> Share

  69. HUANG D, Li F, Lin S, Xia J, et al
    A novel prognostic nomogram based on imaging and molecular parameters for newly diagnosed extranodal natural killer/T-cell lymphoma patients.
    Haematologica. 2024 Aug 15:0. doi: 10.3324/haematol.2024.285362.
    >> Share

  70. RAVIKRISHNAN J, Diaz-Rohena DY, Muhowski E, Mo X, et al
    LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
    Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2023.284353.
    >> Share

  71. HILTON LK
    A nu mouse model of diffuse large B-cell lymphoma in constitutional Atm loss.
    Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285973.
    >> Share

  72. MYERS CS, Williams E, Cornejo CB, Pongas G, et al
    Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations.
    Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285233.
    >> Share

  73. EPSTEIN-PETERSON ZD, Drill E, Aypar U, Batlevi CL, et al
    Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
    Haematologica. 2024;109:2749-2752.
    >> Share

  74. MOSKOWITZ AJ
    Combination chemotherapy for Hodgkin lymphoma.
    Haematologica. 2024;109:2383-2384.
    >> Share

    July 2024
  75. HOLST JM, Pedersen MB, Enemark MB, Hansen MC, et al
    Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma.
    Haematologica. 2024 Jul 25. doi: 10.3324/haematol.2023.283798.
    >> Share

  76. MELODY M, Gordon LI
    Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.
    Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285255.
    >> Share

  77. GARGANO G, Vegliante MC, Esposito F, Pappagallo SA, et al
    A targeted gene signature stratifying mediastinal gray zone lymphoma into classical HL-like or PMBL-like subtypes.
    Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285266.
    >> Share

  78. OTHMAN T, Frankel P, Allen P, Popplewell LL, et al
    Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.
    Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285185.
    >> Share

  79. WANG L
    Have we truly uncovered the key to primary vitreoretinal lymphoma's pathway to the central nervous system?
    Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.286056.
    >> Share

  80. SERNA A, Navarro V, Iacoboni G, Lopez L, et al
    Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.
    Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285219.
    >> Share

  81. DOURTHE ME, Auperin A, Rigaud C, Barbati M, et al
    Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with rituximab.
    Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285403.
    >> Share

  82. DE JONGE AV, Bruins WSC, Duetz C, Korst CLBM, et al
    Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T-cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.
    Haematologica. 2024 Jul 4. doi: 10.3324/haematol.2024.285170.
    >> Share

  83. SALVINO MA, Domingo-Domenech E, Sureda A
    The importance of secondary cancer screening programs in Hodgkin lymphoma survivors.
    Haematologica. 2024 Jul 4. doi: 10.3324/haematol.2023.284609.
    >> Share

  84. AL-SAWAF O
    High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies.
    Haematologica. 2024;109:2035-2037.
    >> Share

  85. SONG Y, Cao J, Zhang Q, Li C, et al
    Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
    Haematologica. 2024;109:2165-2176.
    >> Share

    June 2024
  86. KASPRZYK ME, Sura W, Podralska M, Kazimierska M, et al
    Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen.
    Haematologica. 2024 Jun 27. doi: 10.3324/haematol.2023.284672.
    >> Share

  87. HERBAUX C, Bret C, Bachy E, Bories P, et al
    Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.
    Haematologica. 2024 Jun 20. doi: 10.3324/haematol.2023.284786.
    >> Share

  88. BENJAMINI O, Fried S, Shouval R, Flynn JR, et al
    Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma.
    Haematologica. 2024 Jun 20. doi: 10.3324/haematol.2023.284664.
    >> Share

  89. KAPHAN E, Bettega F, Vallet N, Fegueux N, et al
    PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2024.284968.
    >> Share

  90. CHENG J, Xi L, Jang Y, Kim J, et al
    An investigation of germline variants of HAVCR2 in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2023.284738.
    >> Share

  91. IZUMIYAMA K, Inao T, Goto H, Harada S, et al
    Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2023.284841.
    >> Share

  92. DAVIES N, Francis T, Oldreive C, Azam M, et al
    Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.
    Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.284404.
    >> Share

  93. YOSHIFUJI K, Sadato D, Toya T, Motomura Y, et al
    Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma.
    Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.284953.
    >> Share

  94. RAI S, Kim WS, Ando K, Choi I, et al
    Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
    Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.283992.
    >> Share

    May 2024
  95. DANILOV AV, Flinn IW, Davids MS, Gregory B, et al
    The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.
    Haematologica. 2024 May 30. doi: 10.3324/haematol.2024.285043.
    >> Share

  96. GHIONE P, Salles G
    Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
    Haematologica. 2024 May 30. doi: 10.3324/haematol.2022.282362.
    >> Share

  97. YADIGAROGLU K, Scharf S, Gretser S, Schafer H, et al
    Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma.
    Haematologica. 2024 May 23. doi: 10.3324/haematol.2023.284512.
    >> Share

  98. ELICE F, Sommaggio R, Cappuzzello E, Riva M, et al
    A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report.
    Haematologica. 2024 May 9. doi: 10.3324/haematol.2023.284881.
    >> Share

  99. RENAUD L, Wencel J, Pages A, Al Jijakli A, et al
    Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
    Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.284689.
    >> Share

    April 2024
  100. LINK BK
    Follicular lymphoma treatment decisions: put GELF on the shelf?
    Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285286.
    >> Share

  101. CAIRO MS
    TP3 binding domain mutations are bad news in Burkitt lymphoma.
    Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2024.285213.
    >> Share

  102. BOURLON C, Roddie C, Menne T, Norman J, et al
    Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
    Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010.
    >> Share

  103. IKEDA D, Oura M, Uehara A, Tabata R, et al
    Prognostic relevance of tumor-infiltrating CD4(+) cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma.
    Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285038.
    >> Share

    March 2024
  104. BI C, Huang Y, Ali R, Wang F, et al
    MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications.
    Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2023.283811.
    >> Share

  105. PULCZYNSKI EJ, Simonsen MR, Kuittinen O, Fagerli UM, et al
    Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.
    Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285207.
    >> Share

  106. WIGHT J, Blombery P, Lickiss J, Burgess M, et al
    Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance.
    Haematologica. 2024 Mar 21. doi: 10.3324/haematol.2023.284600.
    >> Share

  107. IANNITTO E, Ferrero S, Bommier C, Drandi D, et al
    Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
    Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109.
    >> Share

  108. ZHU ML, Drill E, Joffe E, Salles G, et al
    Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
    Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284565.
    >> Share

  109. TOLLEY ER, Lewinter C, Pedersen LM, Nielsen TH, et al
    Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.
    Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284281.
    >> Share

  110. BARRACLOUGH A, Agrawal S, Talaulikar D, Chong G, et al
    Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.
    Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284538.
    >> Share

    February 2024
  111. DURAND R, Bellanger C, Kervoelen C, Tessoulin B, et al
    Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284345.
    >> Share

  112. MARTIRE G, Lovisa F, Carraro E, Rizzato D, et al
    TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284868.
    >> Share

  113. STATHIS A, Pirosa MC, Orsucci L, Feugier P, et al
    IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
    Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918.
    >> Share

  114. YUAN X, Xie Y, Xu N, Liu H, et al
    Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
    Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834.
    >> Share

  115. SAVAGE KJ, De Leval L
    Erratum to: Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization.
    Haematologica. 2024;109:693-694.
    >> Share

  116. KUPPERS R
    Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas.
    Haematologica. 2024;109:376-378.
    >> Share

  117. CARBO-MEIX A, Guijarro F, Wang L, Grau M, et al
    BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.
    Haematologica. 2024;109:493-508.
    >> Share

    January 2024
  118. DESMARES A, Bouzy S, Thonier F, Goustille J, et al
    Hepatosplenic T-cell lymphoma displays an original oyster-shell cytological pattern and a distinct genomic profile from that of gamma-delta T-cell large granular lymphocytic leukemia.
    Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.283856.
    >> Share

  119. TUN AM, Wang Y, Maliske S, Micallef I, et al
    Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
    Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2023.284704.
    >> Share

  120. SAVAGE KJ, Slack GW
    Erratum to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome.
    Haematologica. 2024;109:365.
    >> Share

    December 2023
  121. SAVAGE KJ, De Leval L
    Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization.
    Haematologica. 2023;108:3204-3210.
    >> Share

  122. LEWIS NE, Zhou T, Dogan A
    Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.
    Haematologica. 2023;108:3261-3277.
    >> Share

  123. STUVER R, Epstein-Peterson ZD, Horwitz SM
    Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.
    Haematologica. 2023;108:3244-3260.
    >> Share

  124. BISIG B, Savage KJ, De Leval L
    Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.
    Haematologica. 2023;108:3227-3243.
    >> Share

  125. NGU HS, Savage KJ
    Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
    Haematologica. 2023;108:3211-3226.
    >> Share

  126. LACAN C, Caron J, Tarantino N, Fouquet B, et al
    CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.
    Haematologica. 2023;108:3485-3490.
    >> Share

  127. ZHANG L, Zhu X, Qu W, Lu Y, et al
    Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PCM1::JAK2 with erythroblastic sarcoma: a case report and literature review.
    Haematologica. 2023;108:3506-3510.
    >> Share

    November 2023
  128. JALLOUK AP, Kui N, Sun R, Westin JR, et al
    Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
    Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.284453.
    >> Share

  129. MAURER MJ, Casulo C, Larson MC, Habermann TM, et al
    Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
    Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283737.
    >> Share

  130. CARRAS S, Torroja A, Emadali A, Montaut E, et al
    Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
    Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283724.
    >> Share

  131. BROADBENT R, Crosbie P, Armitage CJ, Taylor B, et al
    Pilot study of lung cancer screening for survivors of Hodgkin lymphoma.
    Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.283287.
    >> Share

  132. HOFFMANN MS
    Routine consolidation of early stage primary bone lymphoma with radiation therapy does not improve outcomes.
    Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.284303.
    >> Share

  133. DE CONINCK S, De Smedt R, Lintermans B, Reunes L, et al
    Targeting hyperactive platelet-derived growth factor receptor-beta signaling in T-cell acute lymphoblastic leukemia and lymphoma.
    Haematologica. 2023 Nov 9. doi: 10.3324/haematol.2023.283981.
    >> Share

  134. MAYR F, Kruse V, Fuhrmann DC, Wolf S, et al
    SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism.
    Haematologica. 2023 Nov 2. doi: 10.3324/haematol.2023.283663.
    >> Share

  135. MAURER MJ
    The International Prognostic Index in aggressive B-cell lymphoma.
    Haematologica. 2023;108:2874-2879.
    >> Share

  136. LEIVONEN SK, Friman T, Autio M, Vaittinen S, et al
    Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas.
    Haematologica. 2023;108:3044-3057.
    >> Share

    October 2023
  137. LIA K, Jorgensen RRK, L Wold B, Fluge O, et al
    Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study.
    Haematologica. 2023 Oct 26. doi: 10.3324/haematol.2023.283721.
    >> Share

  138. KUMAR A
    MYC overexpression: adding another piece to the puzzle of high-risk mantle cell lymphoma.
    Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.284105.
    >> Share

  139. REZAZADEH A, Szabo A, Khurana A, Inwards DJ, et al
    Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
    Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283210.
    >> Share

  140. SONG YQ, Zhang HL, Huang HQ, Zhang QY, et al
    Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
    Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283802.
    >> Share

  141. MEEUWES FO, Brink M, Plattel W, Van der Poel MWM, et al
    Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
    Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283174.
    >> Share

  142. CROSSWELL HE, LaCasce AS, Bartlett NL, Straus DJ, et al
    Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
    Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283303.
    >> Share

  143. KAWATA T, Shimizu T, Shindo T, Fujiwara K, et al
    Tucidinostat restores CCR4 expression in adult T-cell leukemia/lymphoma.
    Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283266.
    >> Share

  144. HO C, Smith SD
    More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma.
    Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.284056.
    >> Share

  145. PASTORCZAK A, Szmyd B, Braun M, Madzio J, et al
    Clinical and laboratory diversity of diffuse large B-cell lymphomas in children with Nijmegen breakage syndrome.
    Haematologica. 2023;108:2808-2813.
    >> Share

    September 2023
  146. KHANLARI M, Wang W, Liu YC, Wang L, et al
    Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical STIL::TAL1 fusion events.
    Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283585.
    >> Share

  147. FLOWERS CR, Matasar MJ, Herrera AF, Hertzberg M, et al
    Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283557.
    >> Share

  148. FEHNIGER TA, Watkins MP, Ezenwajiaku N, Wan F, et al
    A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
    Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2022.282246.
    >> Share

  149. ROSCHEWSKI M, Hodson DJ
    Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
    Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613.
    >> Share

  150. FUKANO R, Iijima-Yamashita Y, Iwafuchi H, Nakazawa A, et al
    Prognostic value of minimal disseminated disease assessed using digital PCR for 3'ALK assays in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Haematologica. 2023 Sep 7. doi: 10.3324/haematol.2023.282812.
    >> Share

  151. LUMINARI S
    Prognostic tools for older patients with diffuse large B-cell lymphoma: complex patients require complex solutions and a personal touch.
    Haematologica. 2023;108:2269-2270.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016